Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.54 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 2/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28650527 | 1.00 | HSD11B1 (0.54) | HSD11B1PTGER3ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3974078 | 0.80 | HSD11B1 (0.51) | HSD11B1CYP2C19MEN1KMT2A | |
| SCHEMBL16984808 | 0.79 | HSD11B1 (0.41) | HSD11B1PTGER3MAPTCASRMEN1 | |
| SCHEMBL25276584 | 0.77 | HSD11B1 (0.57) | HSD11B1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25276585 | 0.77 | HSD11B1 (0.57) | HSD11B1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25687839 | 0.77 | HSD11B1 (0.57) | HSD11B1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27834509 | 0.76 | HCRTR1 (0.49) | ALDH1A1CYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL27834512 | 0.76 | L3MBTL1 (0.46) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL28353609 | 0.75 | CHRM2 (0.36) | HSD11B1PTGER3ALDH1A1MAPT | |
| SCHEMBL8983498 | 0.74 | ALDH1A1 (0.46) | HSD11B1ALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113548994-A | Preparation method of (S) -3- (2, 2, 2-trifluoroethyl) -pyrrolidine hydrochloride | 西安都创医药科技有限公司 | 2021-10-26 | — | — | CN | claimed |
| US-20240327343-A1 | PREPARATION METHOD OF 3- (2, 2, 2-TRIFLUOROETHYL) PYRROLIDINE HYDROCHLORIDE | Pierre Fabre Médicament (FR) | 2024-10-03 | — | — | US | disclosed |
| CN-118715203-A | Preparation method of 3- (2, 2-trifluoroethyl) pyrrolidine hydrochloride | 皮埃尔法布雷医药公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-113548994-A | Preparation method of (S) -3- (2, 2, 2-trifluoroethyl) -pyrrolidine hydrochloride | 西安都创医药科技有限公司 | 2021-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327343-A1 | PREPARATION METHOD OF 3- (2, 2, 2-TRIFLUOROETHYL) PYRROLIDINE HYDROCHLORIDE | TET3, PEF1, TET2 | HSD11B1 3350/4885PTGER3 2683/4885ALDH1A1 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.